Article info
PDFOriginal article
Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12
- Correspondence to Dr Simon John Whitehead, Department of Clinical Biochemistry, New Cross Hospital, Wednesfield Rd, Wolverhampton WV10 0QP, UK; simonwhitehead{at}nhs.net
Citation
Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12
Publication history
- Received January 10, 2017
- Revised April 17, 2017
- Accepted April 18, 2017
- First published July 22, 2017.
Online issue publication
June 14, 2020
Article Versions
- Previous version (20 November 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.